Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Benign prostatic hyperplasia. Practical treatment guidelines

T Tammela1

  • 1Division of Urology, Tampere University Hospital, Finland. loteta@uta.fi

Drugs & Aging
|May 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study.

Prostate cancer and prostatic diseases·2011
Same author

Erectile dysfunction as a risk factor for coronary heart disease: implications for prevention.

International journal of clinical practice·2007
Same author

The story of the European Randomized Study of Screening for Prostate Cancer.

BJU international·2004
Same author

[When is an andrologist needed?].

Duodecim; laaketieteellinen aikakauskirja·2002
Same author

[Male sexual dysfunction].

Duodecim; laaketieteellinen aikakauskirja·2002
Same author

[Treatments of benign prostatic hypertrophy and their cost-benefit relationship].

Duodecim; laaketieteellinen aikakauskirja·2002
Same journal

Targeted Treatment for Hyperuricemia: The Drug Pipeline.

Drugs & aging·2026
Same journal

Efficacy and Safety of Ciprofol Versus Propofol for Anesthesia in Older Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Drugs & aging·2026
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
Same journal

Development and Validation of Prescribing Appropriateness Criteria (PAC) for Sri Lankan Older Adults.

Drugs & aging·2026
See all related articles

Benign prostatic hyperplasia (BPH) treatments include surgery and medications like alpha-blockers and 5 alpha-reductase inhibitors. Treatment choice depends on symptom severity, prostate size, patient preference, and risk factors.

Area of Science:

  • Urology
  • Geriatrics
  • Pharmacology

Background:

  • Symptomatic benign prostatic hyperplasia (BPH) significantly impacts older men's quality of life.
  • Transurethral resection of the prostate (TURP) and open prostatectomy are effective but carry risks.
  • Alternative therapies are needed for BPH patients, especially those with moderate symptoms or high surgical risk.

Purpose of the Study:

  • To review current and emerging therapeutic options for symptomatic benign prostatic hyperplasia (BPH).
  • To compare the efficacy and adverse event profiles of surgical and medical BPH treatments.
  • To guide clinicians in selecting the most appropriate BPH treatment based on individual patient factors.

Main Methods:

  • Review of existing literature on BPH therapies, including surgical procedures and pharmacological agents.

Related Experiment Videos

  • Comparison of outcomes for transurethral resection of the prostate (TURP), minimally invasive procedures, and medical treatments.
  • Analysis of efficacy, adverse events, and patient compliance associated with different treatment modalities.

    • Main Results:

    • Transurethral incision of the prostate is effective for smaller prostates (<30g) with minimal adverse effects.
    • Minimally invasive procedures offer efficacy between TURP and medical therapy, with shorter recovery times and suitability for high-risk patients.
    • Medical therapies, including androgen suppression and alpha-adrenoceptor blockade, show 15-20% improvement in urinary flow and symptoms compared to placebo.
    • Finasteride (5 alpha-reductase inhibitor) requires 6-12 months for full effect and is suitable for prostates >40ml.
    • Alpha-1-adrenoceptor antagonists like tamsulosin offer once-daily dosing and minimal blood pressure effects, while non-selective blockers may benefit hypertensive patients.

    Conclusions:

    • A range of effective BPH treatments exist, from TURP to minimally invasive options and medical therapies.
    • The choice of BPH treatment should be individualized, considering symptom severity, prostate size, patient comorbidities, and personal preference.
    • Medical therapies are increasingly important for moderate BPH symptoms, offering well-tolerated and effective symptom relief.